NEUROCRINE BIOSCIENCES INC (NBIX) Stock Price, Quote, News and Overview
NASDAQ:NBIX - Nasdaq - US64125C1099 - Common Stock - Currency: USD
NBIX Quote, Performance and Key Statistics
120.18
+1.06 (+0.89%)
The current stock price of NBIX is 120.18 USD. In the past month the price increased by 12.6%. In the past year, price decreased by -13.79%.
NBIX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.84 | 323.71B | ||
| AMGN | AMGEN INC | 13.09 | 146.07B | ||
| GILD | GILEAD SCIENCES INC | 13.87 | 133.56B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.28 | 63.52B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.81B | ||
| ARGX | ARGENX SE - ADR | 100.1 | 35.88B | ||
| ONC | BEIGENE LTD-ADR | 6.17 | 26.10B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.72B | ||
| NTRA | NATERA INC | N/A | 20.94B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.20B | ||
| BIIB | BIOGEN INC | 7.95 | 18.43B |
Related stock screener links
About NBIX
Company Profile
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 1,800 full-time employees. The firm is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
Company Info
NEUROCRINE BIOSCIENCES INC
6027 Edgewood Bend Court
San Diego CALIFORNIA 92130 US
CEO: Kevin C. Gorman
Employees: 1800
Phone: 18586177600
NEUROCRINE BIOSCIENCES INC / NBIX FAQ
What is the stock price of NEUROCRINE BIOSCIENCES INC today?
The current stock price of NBIX is 120.18 USD. The price increased by 0.89% in the last trading session.
What is the ticker symbol for NEUROCRINE BIOSCIENCES INC stock?
The exchange symbol of NEUROCRINE BIOSCIENCES INC is NBIX and it is listed on the Nasdaq exchange.
On which exchange is NBIX stock listed?
NBIX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NEUROCRINE BIOSCIENCES INC stock?
32 analysts have analysed NBIX and the average price target is 158.86 USD. This implies a price increase of 32.18% is expected in the next year compared to the current price of 120.18. Check the NEUROCRINE BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NEUROCRINE BIOSCIENCES INC worth?
NEUROCRINE BIOSCIENCES INC (NBIX) has a market capitalization of 11.89B USD. This makes NBIX a Large Cap stock.
How many employees does NEUROCRINE BIOSCIENCES INC have?
NEUROCRINE BIOSCIENCES INC (NBIX) currently has 1800 employees.
What are the support and resistance levels for NEUROCRINE BIOSCIENCES INC (NBIX) stock?
NEUROCRINE BIOSCIENCES INC (NBIX) has a support level at 120.17 and a resistance level at 120.3. Check the full technical report for a detailed analysis of NBIX support and resistance levels.
Is NEUROCRINE BIOSCIENCES INC (NBIX) expected to grow?
The Revenue of NEUROCRINE BIOSCIENCES INC (NBIX) is expected to grow by 13.93% in the next year. Check the estimates tab for more information on the NBIX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NEUROCRINE BIOSCIENCES INC (NBIX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NBIX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NBIX, evaluating the profitability, health, valuation and growth aspects
- NEUROCRINE BIOSCIENCES INC (NBIX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEUROCRINE BIOSCIENCES INC (NBIX) Sales and EPS estimates to see what analysts future expectations are.
- NEUROCRINE BIOSCIENCES INC (NBIX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEUROCRINE BIOSCIENCES INC (NBIX) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEUROCRINE BIOSCIENCES INC (NBIX) Stock Chart to make your own analysis
- NEUROCRINE BIOSCIENCES INC (NBIX) Latest news and press-releases to stay up to date.
Does NEUROCRINE BIOSCIENCES INC (NBIX) stock pay dividends?
NBIX does not pay a dividend.
When does NEUROCRINE BIOSCIENCES INC (NBIX) report earnings?
NEUROCRINE BIOSCIENCES INC (NBIX) will report earnings on 2025-07-30, before the market open.
What is the Price/Earnings (PE) ratio of NEUROCRINE BIOSCIENCES INC (NBIX)?
The PE ratio for NEUROCRINE BIOSCIENCES INC (NBIX) is 40.74. This is based on the reported non-GAAP earnings per share of 2.95 and the current share price of 120.18 USD. Check the full fundamental report for a full analysis of the valuation metrics for NBIX.
What is the Short Interest ratio of NEUROCRINE BIOSCIENCES INC (NBIX) stock?
The outstanding short interest for NEUROCRINE BIOSCIENCES INC (NBIX) is 4.63% of its float. Check the ownership tab for more information on the NBIX short interest.
NBIX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to NBIX. When comparing the yearly performance of all stocks, NBIX is a bad performer in the overall market: 66.04% of all stocks are doing better.
NBIX Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to NBIX. NBIX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
NBIX Financial Highlights
Over the last trailing twelve months NBIX reported a non-GAAP Earnings per Share(EPS) of 2.95. The EPS decreased by -18.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.49% | ||
| ROA | 9.18% | ||
| ROE | 13.18% | ||
| Debt/Equity | 0 |
NBIX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to NBIX. The Buy consensus is the average rating of analysts ratings from 32 analysts.
For the next year, analysts expect an EPS growth of 21.88% and a revenue growth 13.93% for NBIX